Premium
Sacubitril/valsartan for chronic heart failure: its future potential
Author(s) -
Chaplin Steve
Publication year - 2016
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1514
Subject(s) - medicine , valsartan , sacubitril , heart failure , sacubitril, valsartan , ejection fraction , cardiology , angiotensin receptor , neprilysin , pharmacology , angiotensin ii , intensive care medicine , receptor , blood pressure , biochemistry , chemistry , enzyme
Sacubitril/valsartan (Entresto), a combined neprilysin inhibitor/angiotensin II‐receptor antagonist for the treatment of chronic heart failure with reduced ejection fraction, was launched in the UK in January. The phase 3 clinical trial PARADIGM‐HF established its efficacy in chronic heart failure but what is its future place in therapy, according to the latest guidelines and research?